Alder
AcquiredAlder is a biotech company in Bothell, United States, founded in 2004. It has raised $94.0M across 3 rounds, most recently a $38.0M Series D in April 2012.
- Headquarters
- Bothell, Washington
- Founded
- 2004
- Business Model
- B2B
- Total Funding
- $94.0M
- Last Round
- $38.0M Series DApr 2012
- Rounds
- 3
- Acquisition Date
- Sep 2019
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 6 investors for this company. The full record is or through the API.
About
Alder BioPharmaceuticals (now Lundbeck Seattle Biopharmaceuticals) was a Bothell, Washington-based clinical-stage biopharmaceutical company founded in 2004 that discovered, developed, and manufactured therapeutic monoclonal antibodies for migraine, cancer, pain, cardiovascular, and autoimmune/inflammatory diseases. It went public on Nasdaq in May 2014, and in September 2019 was acquired by Denmark's H. Lundbeck A/S in a deal valued at up to $1.95 billion, becoming the platform behind the migraine-prevention drug Vyepti (eptinezumab).
Summary
It has raised $94.0M in total across 3 rounds, most recently a $38.0M Series D round in Apr 2012. Investors include Novo Holdings A/S, Delphi Ventures and H.I.G. Capital.
Funding & Exit History
Sep 2019
Sign up to see all 5 events
Funding: Series B through Series D. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/alder"><img src="https://indexed.vc/api/badge/company/alder" alt="Alder on Indexed.vc" width="260" height="76" /></a>